Actualités et Activités de Immunocore
Dirigeants
Voir l'organigramme avec ses 29 principaux dirigeants
Biographies les plus recherchées chez Immunocore
- Bahija Jallal, Chief Executive Officer and Director
- Siddharth Kaul, Non-Executive Director
- Peter Ratcliffe, Non-Executive Director
Changements de dirigeants chez Immunocore
- Mohammed Dar qui était Head of Clinical Development and Chief Medical Officer, est promu Executive Vice President, Clinical Development and Chief Medical Officer (publié le 30 janvier 2026).
- David Berman, Head of Research & Development, quittera l'entreprise le 27 févr. 2026 (publié le 30 janvier 2026).
- Tina St. Leger, Chief Human Resources Officer, a quitté l'entreprise (publié le 1 décembre 2025).
Créer une alerte
pour suivre les mouvements de dirigeants chez Immunocore.
Biotechnologie
Immunocore a 2 428 concurrents dont Lonza (Suisse), Vertex Pharmaceuticals (Etats—Unis) et Eurofins (Luxembourg).
Actualités en fusion/acquisition en Biotechnologie.
- Eli Lilly has announced the acquisition of AtaiBeckley (publié le 17 juillet 2026).
- GSK a acquis Nuvalent (publié le 17 juillet 2026).
- Clearside Biomedical has gone out of its bankruptcy protection (publié le 15 juillet 2026).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Immunocore
- Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine :: Immunocore PLC
- Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial :: Immunocore PLC
- Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021 :: Immunocore PLC
- Immunocore to present at upcoming investor conferences :: Immunocore PLC
- Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma :: Immunocore PLC
- Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma :: Immunocore PLC
- Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update :: Immunocore PLC
- Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting :: Immunocore
- Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B :: Immunocore
- Immunocore Reports First Quarter 2021 Financial Results :: Immunocore
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Immunocore
- Immunocore sur Wikipédia, Google News & Yahoo Finance en 1-click
- Immunocore sur LinkedIn, X (Twitter) & YouTube en 1-click
